Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.

We carry these mixed feelings into 2026, which is slated to be another great—yet perhaps troubled—year for science. No list ...

To add to this, this new game apparently has a "bold twist" which is part of a "vision that could only exist on Nintendo ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Monday, December 22, 2025. Let’s ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...